The company, formerly known as Sanofi-Aventis, is engaged in the research, development, manufacturing and marketing of pharmaceutical products. It was formed in 2004 when Sanofi-Synthélabo merged with Aventis. The registered business office of the company is located in Paris, France.The company offers Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. It also provides thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines.The company is considered one of the largest pharmaceutical companies in the world.It is a global company with operating subsidiaries in France, the United States, Singapore, Peru, Colombia, Poland, Brazil, Mexico, the Netherlands, China, Algeria, Belgium, Panama, Thailand, Hong Kong, the Czech Republic, Argentina, Sweden, Hungary, Ireland, the Republic of Korea, Indonesia, Japan, Venezuela, Canada, New Zealand, and Russian Federation.The company has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic Inc., and UCB S.A.
La versione in sola lettura del questionario inviato a questa azienda è disponibile pubblicamente: vedi questionario.